Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
G1 Therapeutics, Inc. (Nasdaq: GTHX) is a commercial-stage oncology biopharmaceutical company committed to developing next-generation therapies to improve the lives of cancer patients. The company is based in Research Triangle Park, N.C., and leverages its proprietary kinase drug discovery platform to advance a pipeline of innovative compounds. G1's flagship product, COSELA® (trilaciclib), has been approved by the FDA to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).
In addition to COSELA, G1 Therapeutics is actively developing and evaluating trilaciclib in combination with other anti-cancer therapies. One notable project is the global, multi-center, randomized, placebo-controlled Phase 3 trial known as PRESERVE 2, which investigates trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). Preliminary results have shown promising survival benefits, indicating trilaciclib’s potential to protect bone marrow and enhance patient outcomes during cytotoxic therapy.
The company also engages in strategic partnerships to broaden its impact. For instance, G1 Therapeutics has entered agreements with companies like Pepper Bio and Jupiter Bioventures to advance the clinical development and commercialization of lerociclib, another promising CDK4/6 inhibitor. These collaborations aim to explore lerociclib's efficacy in treating various cancers, including HCC and radioprotection uses.
On the financial front, G1 Therapeutics reported revenues of $82.5 million for the full year 2023, reflecting significant growth from $51.3 million in the previous year. The company's ongoing commitment to innovation and strategic collaborations underscores its role as a key player in oncology therapeutics.
For more information, visit G1 Therapeutics and follow them on Twitter and LinkedIn.
G1 Therapeutics (Nasdaq: GTHX) announced a virtual COSELA Kickoff Analyst and Investor Summit on April 9, 2021, from 9-11 AM EDT. The summit will discuss the U.S. launch strategy for COSELA, a first-in-class therapy for myeloprotection in extensive-stage small cell lung cancer. Key insights will be provided by Dr. Jared Weiss and Nurse Practitioner Tajuana Bradley, emphasizing the need for proactive treatment against myelosuppression. A webcast will be available for 90 days post-event, and further details can be accessed via G1 Therapeutics' official website.
COSELA Added to NCCN Guidelines
G1 Therapeutics (GTHX) announced that its drug, COSELA™ (trilaciclib), has been included in the updated National Comprehensive Cancer Network (NCCN) Treatment Guidelines for Small Cell Lung Cancer and the Supportive Care Guidelines for Hematopoietic Growth Factors. This inclusion underscores COSELA's significance in cancer management, particularly for those undergoing chemotherapy for extensive-stage small cell lung cancer (ES-SCLC). COSELA is the first proactive multilineage myeloprotection agent aimed at reducing chemotherapy-induced myelosuppression.
On March 5, 2021, G1 Therapeutics, Inc. (GTHX) announced the grant of inducement stock options totaling 14,300 shares to two new employees under its 2021 Inducement Equity Incentive Plan. These options, exercisable at $23.07 per share, are part of the strategy to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with a quarter vesting annually, subject to employment conditions. G1 Therapeutics focuses on developing next-generation cancer therapies and is based in Research Triangle Park, N.C.
G1 Therapeutics (Nasdaq: GTHX) announced its participation in two upcoming investor conferences. CEO Jack Bailey will present at the HC Wainwright Global Life Sciences Conference starting March 9, 2021, at 7:00 AM ET. He will also engage in a fireside chat at the Roth 33rd Annual Conference on March 17, 2021, at 10:30 AM ET. Both conferences are virtual, and webcasts can be accessed via the company's website.
G1 Therapeutics focuses on developing therapies to improve cancer treatment, including its product COSELA™.
G1 Therapeutics and Boehringer Ingelheim announce the U.S. launch of COSELA™ (trilaciclib), FDA approved for myeloprotection in extensive-stage small cell lung cancer (ES-SCLC). This innovative therapy is the first to reduce chemotherapy-induced myelosuppression. Patients can access COSELA through specialty distributors and will be supported by the G1 to One™ Patient Support Program, designed to help with coverage and affordability. Approximately 30,000 cases of SCLC are treated annually in the U.S., emphasizing the need for effective treatment options.
G1 Therapeutics (GTHX) announced the FDA approval of COSELA™ (trilaciclib) as the first therapy for reducing chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer. Commercial availability is expected in early March 2021. The company plans to initiate three additional clinical trials in the first half of 2021, exploring COSELA's efficacy across multiple cancer types.
Q4 2020 financials revealed a net loss of $25.3 million, down from $35.4 million in Q4 2019, with cash and equivalents totaling $207.3 million.
G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call on February 24, 2021, at 4:30 p.m. ET to provide a corporate and financial update for Q4 2020 and the full year. Interested parties can join by dialing (866) 763-6020 for domestic calls or (210) 874-7713 for international calls, using conference code 5267698. The event will be accessible via the company’s Events & Presentations page. G1 Therapeutics focuses on developing therapies for cancer, including its product COSELA™ (trilaciclib) and has a pipeline for various solid tumors.
G1 Therapeutics announced FDA approval for COSELA (trilaciclib), the first therapy to offer myeloprotection for patients with extensive-stage small cell lung cancer (ES-SCLC) undergoing chemotherapy. This innovative treatment reduces the incidence and duration of severe neutropenia and related complications, enhancing patient quality of life. COSELA will be available through specialty distributors in early March 2021. Clinical trials demonstrated significant reductions in myelosuppression-related issues. Post-marketing studies will follow to monitor COSELA's long-term impact.
G1 Therapeutics (Nasdaq: GTHX) announced that CEO Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference on February 11, 2021, at 2:00 PM ET. This virtual event will feature a fireside chat, accessible via a live webcast. G1 Therapeutics is focused on developing innovative cancer therapies, including Trilaciclib, which has received Breakthrough Therapy Designation and is under FDA review with a PDUFA date of February 15, 2021, and Rintodestrant, aimed at treating ER+ breast cancer.
G1 Therapeutics, a clinical-stage oncology company, announced that CEO Jack Bailey will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:50 p.m. ET. The presentation will be accessible via a live and archived webcast on the company’s events page. G1 Therapeutics focuses on developing therapies to improve cancer treatment outcomes, including Trilaciclib, which is under FDA review with a PDUFA action date of February 15, 2021, and Rintodestrant, aimed at treating ER+ breast cancer.
FAQ
What is the current stock price of G1 Therapeutics (GTHX)?
What is the market cap of G1 Therapeutics (GTHX)?
What does G1 Therapeutics, Inc. specialize in?
What is COSELA® (trilaciclib)?
What is the PRESERVE 2 trial?
Where is G1 Therapeutics, Inc. located?
Who are G1 Therapeutics' key partners?
What recent financial achievements has G1 Therapeutics reported?
What is lerociclib?
How can I get more information about G1 Therapeutics?
What types of cancer are G1 Therapeutics’ therapies targeting?
What are G1 Therapeutics’ future goals?
